Introduction {#sec1-1}
============

A hallmark feature of autoimmune pulmonary alveolar proteinosis (APAP) is accumulation of excessive amounts of surfactant in the lung. The fundamental mechanism was proven to be production of autoantibodies against granulocyte macrophage colony-stimulating factor (GM-CSF), which is essential for surfactant clearance by maturation and proliferation of alveolar macrophages (AM) ([@ref1],[@ref2]). Smoking and inhalation of dust have been suggested to accelerate the occurrence of APAP ([@ref3],[@ref4]), but precise epidemiologic studies have not been performed. A case of APAP that appeared to be linked to smoking is presented.

Case Report {#sec1-2}
===========

A 46-year-old man with mild bronchial asthma presented with dyspnea and widespread shadows in the lung. He had a 52-pack-year smoking background. Lung computed tomography (CT) scan revealed diffuse ground glass opacities with peripheral sparing. Bronchoalveolar lavage, transbronchial lung biopsy ([Figure 1](#F1){ref-type="fig"}), and measurement of serum anti-GM-CSF IgG yielded results consistent with APAP.

![Histopathology of the lung obtained by transbronchial biopsy shows accumulation of periodic acid Schiff-positive materials in the alveolar spaces](SVDLD-34-257-g001){#F1}

Since his PaO~2~ was below 60 mmHg on room air, he was advised to stop smoking 40 cigarettes with high tar content (10 mg) per day and to continue inhalation of medium-dose fluticasone/salmeterol before undergoing three times of unilateral whole lung lavage (WLL). Despite these preparations, the WLL procedures failed or were incomplete because of bronchoconstriction and decreased compliance of the ventilated lung. Because he still needed oxygen inhalation and lung shadows on CT scan improved minimally, a fourth unilateral WLL was planned. One day before the scheduled WLL, he was noted to be stable without the need for oxygen inhalation and lung shadows were markedly improved. Therefore, the fourth WLL was canceled and he was followed-up instead.

Five months after the last WLL, the patient was doing very well and lung shadows improved further ([Figure 2](#F2){ref-type="fig"}). He had continued cessation of cigarette use at that time. However, at 13 months after the last WLL, an apparent relapse was observed on CT scan ([Figure 2](#F2){ref-type="fig"}). He confessed that he had resumed smoking 20 cigarettes (10 cigarettes with 6 mg of tar and 10 cigarettes with 1 mg of tar) daily after the previous visit. Despite our strong recommendation of abstention from smoking, the best he could do was change the cigarette brand to one with less tar content (20 cigarettes with 1 mg of tar per day). Apparent but modest improvement of lung shadows was observed 2 months later ([Figure 2](#F2){ref-type="fig"}). Shadows of similar density persisted at 5 months after transition to low-tar cigarettes. Serum autoantibody levels transiently decreased following WLL, but these returned to the initial levels at the time of remission and remained constant while the lung shadows changed ([Figure 1](#F1){ref-type="fig"}). On the other hand, serum levels of Krebs von den Lungen-6 (KL-6), a sialylated glycoprotein expressed by alveolar type 2 cells and one of the biomarkers of alveolar proteinosis, well paralleled the changes in the lung shadows ([Figure 1](#F1){ref-type="fig"}). Respiratory function and percutaneous oxygen saturation did not change significantly while the lung shadows fluctuated.

![Clinical course of a 46-year-old man with autoimmune pulmonary alveolar proteinosis. IgG antibody against GM-CSF was measured by enzyme-linked immunosorbent assay using polyclonal reference IgG antibody purified from 10 patients with autoimmune pulmonary alveolar proteinosis. GM-CSF, granulocyte macrophage colony-stimulating factor; KL-6, Krebs von den Lungen-6](SVDLD-34-257-g002){#F2}

Discussion {#sec1-3}
==========

In this case, the changes in lung shadows as seen by CT scan seemed to be strongly affected by smoking. Spontaneous resolution and exacerbation were least likely, given the consistent close correlation between disease fluctuation and smoking. In addition, the development of APAP might have been accelerated by heavy smoking. The extent of the CT shadows well correlated with the total amounts of tar indicated on the cigarette packs. The amount of tar in a given cigarette brand is measured by an inhalation machine under the condition stipulated and may not be an accurate indicator of the amount of tar actually inhaled by smokers. Nevertheless, the amounts can be surrogate indicators of not only tar content, but also nicotine and all other constituents in cigarette smoke, as the amounts of constituents in cigarettes are correlated with each other ([@ref5]). Smoking has been reported to impair the phagocytic activity of AM, which may be relevant to the pathogenesis of APAP ([@ref6],[@ref7]).

In conclusion, the present case supported the idea that smoking may be a risk factor for the development and persistence of APAP in some patients. However, the reported incidence of smoking in patients with APAP at disease onset has been variable ([@ref8]-[@ref10]). Well-designed case-control studies are needed to draw a definite conclusion on this issue.
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